Abstract:

Biosynthesized cellulose is produced by the bacteria, Acetobacter xylinum, and possesses unique properties not present in other biomaterials. The material is formed during fermentation having a multi-layered structure composed of fine, nonwoven, cellulose hydrophilic fibers. This structure allows biosynthesized cellulose to have a high-fluid capacity, superior strength, and biocompatibility, which makes it suitable for topical and implantable biomedical applications. Initial product development of biosynthesized cellulose has focused on advanced wound-care applications. The product, XCell® (Xylos® Corporation, Langhorne, PA, USA), has been bioengineered to have the ability to both donate and absorb moisture, depending on the wound environment. Comparative bench testing has shown that XCell® is the only wound dressing with this unique dual-fluid-handling capability. The product has been studied thoroughly using animal models and proved to be safe and biocompatible. Human clinical testing has demonstrated its effectiveness in providing a moist environment, essential to treating hard-to-heal chronic wounds. The major clinical benefits of the product include: 1) help in removal of non-viable tissue and promotion of autolytic debridement, which results in increased granulation tissue; 2) cleansing of wound margins that leads to epithelial migration and reduction of wound size; and 3) healing of various types of chronic wounds.

Authors:

Victor H.Frankel, M.D., Ph.D., K.N.O.- Hospital for Joint Diseases Orthopaedic Institute, New York, New York; Gonzalo C.Serafica, Ph.D.-Xylos® Corporation, Langhorne, Pennsylvania; Christopher J.Damien, Ph.D.-Xylos® Corporation, Langhorne, Pennsylvania

For Direct IP Access please click this link